Rebranding asymptomatic type 1 diabetes: the case for autoimmune beta cell disorder as a pathological and diagnostic entity

Diabetologia

Volumn 60, Issue 1, 2017, Pages 35-38

  Bonifacio, Ezio ^a,b   Mathieu, Chantal ^c   Nepom, Gerald T ^d   Ziegler, Anette G ^e,f   Anhalt, Henry ^g   Haller, Michael J ^h   Harrison, Leonard C ^i,j   Hebrok, Matthias ^k   Kushner, Jake A ^l   Norris, Jill M ^m   Peakman, Mark ^n,o   Powers, Alvin C ^p,q   Todd, John A ^r   Atkinson, Mark A ^h  

^a CENTER FOR REGENERATIVE THERAPIES DRESDEN   (Germany)

^b DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^e INSTITUTE OF EPIDEMIOLOGY   (Germany)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^g T1D Exchange   (United States)

^h UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

ⁱ WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^j UNIVERSITY OF MELBOURNE   (Australia)

^k UNIVERSITY OF CALIFORNIA   (United States)

^l BAYLOR COLLEGE OF MEDICINE   (United States)

^m UNIVERSITY OF COLORADO   (United States)

ⁿ KING'S COLLEGE LONDON   (United Kingdom)

^o GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

^p VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^q VETERANS AFFAIRS MEDICAL CENTER   (United States)

^r UNIVERSITY OF CAMBRIDGE   (United Kingdom)

more..

Author keywords

Autoimmunity; Beta cell; Diabetes; Disease classification

Indexed keywords

ARTICLE; ASYMPTOMATIC DISEASE; AUTOIMMUNE BETA CELL DISORDER; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CHILDHOOD DISEASE; CLINICAL EFFECTIVENESS; DISEASE CLASSIFICATION; DRUG INDUSTRY; HEALTH INSURANCE; HOSPITAL COST; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INTERNATIONAL CLASSIFICATION OF DISEASES; MEDICAL TERMINOLOGY; PANCREAS ISLET BETA CELL; PANCREAS ISLET DISEASE; PERSONALIZED MEDICINE; PRACTICE GUIDELINE; PRIORITY JOURNAL; COMPLICATION; IMMUNOLOGY; PATHOLOGY; PHYSIOLOGY;

AUTOIMMUNITY; DIABETES MELLITUS, TYPE 1; HUMANS; INSULIN-SECRETING CELLS;

EID: 84992372038     PISSN: 0012186X     EISSN: 14320428     Source Type: Journal    
DOI: 10.1007/s00125-016-4144-8     Document Type: Article

References (9)

1. Atkinson MA, Eisenbarth GS, Michels AW (2014) Type 1 diabetes. Lancet 383:69–82
2. Ziegler AG, Rewers M, Simell O et al (2013) Seroconversion to multiple islet autoantibodies and risk of progression to diabetes in children. JAMA 309:2473–2479
3. Insel RA, Dunne JL, Atkinson MA et al (2015) Staging presymptomatic type 1 diabetes: a scientific statement of JDRF, the Endocrine Society, and the American Diabetes Association. Diabetes Care 38:1964–1974
4. Elding Larsson H, Vehik K, Gesualdo P et al (2014) Children followed in the TEDDY study are diagnosed with type 1 diabetes at an early stage of disease. Pediatr Diabetes 15:118–126
5. Meehan C, Fout B, Ashcraft J, Schatz DA, Haller MJ (2015) Screening for type 1 diabetes risk to reduce DKA is not economically viable. Pediatr Diabetes 16:565–572
6. Staeva TP, Chatenoud L, Insel R, Atkinson MA (2013) Recent lessons learned from prevention and recent-onset type 1 diabetes immunotherapy trials. Diabetes 62:9–17
7. International Statistical Classification of Diseases and Related Health Problems 10th Revision (2016) Available from www.who.int/classifications/icd/en/. Accessed 7 August 2016
8. Knip M, Selvenius J, Siljander H, Veijola R (2016) Reclassification of asymptomatic beta cell autoimmunity: a critical perspective. Diabetologia. doi:10.1007/s00125-016-4147-5
9. Vehik K, Lynch KF, Schatz DA et al (2016) Reversion of β-cell autoimmunity changes risk of type 1 diabetes: TEDDY study. Diabetes Care 39:1535–1542